Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Australia Biotech Invest & Partnering 2020
16 slides from Optiscan Imaging's conference presentation, Oct 29, 2020
Slide 1: Presentation at Australia Biotech Invest & Partnering 2020
ASX Announcement 29 October 2020 Presentation at Australia Biotech Invest & Partnering 2020 Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) is pleased to announce that the Company’s CEO and Executive Chairman, Mr Darren Lurie, will be presenting at AusBiotech’s Australia Biotech In
Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 25 October 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor ma
Slide 4: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu
Slide 5: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue ▪ 596,730,300 Ordinary Shares Darren Lurie – Executive Chairman B.LLB (Hons) and B.COM (Hons) ▪ 25,600,000 unlisted options Executive Chair since May 2018. Former Group CFO and Head of Corporate Development for EduCo International (an investee compa
Slide 6: OPTISCAN Introduction - Technology
OPTISCAN Introduction - Technology ❑ Hand-held Confocal Endomicroscope for Medical and Research Imaging ❑ World-leading and Patent Protected ❑ Real-time “Virtual Biopsy“ ❑ Reduced and More Targeted Biopsies ❑ Capture all Cancer Cells and reduce Tumour Margin in Surgery
Slide 7: Optiscan FIVE2 Laboratory and InVivage Clinical Systems
Optiscan FIVE2 Laboratory and InVivage® Clinical Systems FIVE2 (ViewnVivo) InVivage® Clinical System Laboratory System For Oral & Breast Cancer
Slide 8: Optiscan Applications and Devices
Optiscan Applications and Devices Clinical Applications and Devices: ❑ Oral Cancer - InVivage® ❑ Breast Cancer - InVivage® ❑ Neurosurgery – CONVIVO® (Carl Zeiss Meditec Co-operation) Pre-clinical Device: FIVE2 (ViewVivo®) ❑ Laboratory & Translational Experiments ❑ Medical Research Facilities and Uni
Slide 9: World Lip & Oral Cavity Cancer Incidence and Mortality
World Lip & Oral Cavity Cancer Incidence and Mortality 2% 350k 177k Of all cancer New cases Total deaths Incidence in 2018 in 2018 >80% 57% 2.5x Survival Survival Cost Early Diagnosis Late Diagnosis Early Vs Late
Slide 10: Oral Cancer Market Size
Oral Cancer Market Size ❑ China ❑ United States 48 Public Tertiary Dental Hospitals 900 Specialist Cancer Centers Guangdong Province: 6,146 Total US Hospitals 158 Stomatology Departments in General Hospitals 9,000 Oral and Maxillofacial Surgeons 14 Public and Private Dental Hospitals Name Location N
Slide 11: OPTISCAN – Oral Cancer Progress
OPTISCAN – Oral Cancer Progress 3 Oral Cancer Studies and Trials ❑ Received Federal Government ~1m A$ grant for 150 patient Oral Cancer Study at Melbourne Dental School (includes $260k payable to Optiscan) ❑ Trial on-going at the Memorial Sloan Kettering Cancer Centre in New York ❑ Trial on-going at
Slide 12: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 15% 8.5% Million 2.1 million new cases of 15% of all 8.5% of all new cancer breast cancer predicted in new Cancer cases in cases in China are breast 2018 (globally) 1 United States are breast 3 cancer 2 cancer • 20-30% of lumpectomy patients currently
Slide 13: CONVIVO – Carl Zeiss Meditech (CZM) Co-operation
CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation ❑FDA 510(k) clearance and CE Mark obtained ❑“this probably is the most exciting technology that I have seen in my career come through the laboratory.” - Mark C Preul, Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States. 297K Brain an
Slide 14: Distribution Model for the Preclinical Device (FIVE2)
Distribution Model for the Preclinical Device (FIVE2) ❑ Asia Pacific Distribution Manager- Dr Joseph Jiafu, PhD ❑ China Distribution Manager- Wei Zhu, BSc ▪ South and West China: Guangzhou Yunxing 3 Sales since late 2019 ▪ East China: Biotimes Technology Limited ❑ North America Distribution ▪ Techni
Slide 15: Outlook
Outlook ▪ Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School. ▪ Commencement of Stage 3 of breast cancer trial at leading Melbourne hospitals ▪ Increased geographical footprint to deliver additional FIVE2 (ViewnVivo) sales ▪ FDA 510(k) Oral imaging submission planned for fi
Slide 16: Darren Lurie, Executive Chairman, Optiscan Imaging Limited
Darren Lurie Executive Chairman Optiscan Imaging Limited (ASX:OIL) www.optiscan.com
Optiscan Imaging — Australia Biotech Invest & Partnering 2020 on 6ix